Recent advances in chirally pure proton pump inhibitors

Journal of the Indian Medical Association

Volumn 105, Issue 8, 2007, Pages 469-474

  Pai, Vikas ^a   Pai, Nitin ^b  

^a Pai Clinic   (India)

^b Department in Internal Medicine ^*

Author keywords

Dexrabeprazole; Esomeprazole; S pantoprazole

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; CHIRALITY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; NONHUMAN; STATISTICAL SIGNIFICANCE; STOMACH ACID; VISUAL ANALOG SCALE;

EID: 39149093995     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Angela Ä, Anderson TB, Antonsson M, Naudot AK, Skȧnberg I, Weidolf L - Steroselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966-72.
2. Olibe L, Carlsson E, Lindberg P - A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Drug Discovery. Nat Rev 2003; 2: 132-9.
3. Furuta T, Ohashi K, Kosuge K - CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-61.
4. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M - Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62: 1503-38.
5. Tonini M, Vigneril S, Savarino V, Scarpignato C - Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 2001; 33: 600-6.
6. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, et al - Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis: a randomised controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
7. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, et al - Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
8. Kromer W, Horbach S, Lühmann R - Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Scand J Gastroenterol 2001; 36: 3-9.
9. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S. Schutze K, et al - A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for the healing of erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-46.
10. Masubuchi N, Yamazaki H, Tanaka M - Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. Chirality 1998; 10: 747.
11. Xie Z, Zhang Y, Xu H, Zhong D - Pharmacokinetic differences between pantoprazole enantiomers in rats. Pharm Res 2005; 22: 1678-84.
12. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K - Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 2001; 69: 108-13.
13. Lamba JK, Dhiman RK, Kohli KK - Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects. Clin Pharmacol Ther 1998; 63: 422-7.
14. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK - CYP2C9 and CYP2C19 genetic polymorphism: frequencies in south Indian population. Fundam Clin Pharmacol 2005; 19:101-5.
15. Cao H, Wang M, Sun L, Ikejima T, Hu Z, Zhao W - Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea pigs. J Pharm Pharmacol 2005; 57: 923-7.
16. Pai VG, Pai NV, Thacker HP, Shinde JK, Mandora VP, Erram SS - Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. World J Gastroenterol 2006; 12: 6017-20.
17. Robinson M - pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther 2004; 20: 232-6.
18. Jaworski T, Sarosick I, Sostarich S, Roeser K, Connor M, Brotze S - Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci 2005; 50: 357-65.
19. Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T - Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2006; 61: 315-20.
20. Bodhankar SL, Jain BB, Ahire BP, Daude RB, Shitole PP - The effect of rabeprazole and its isomers on aspirin and histamine-induced ulcers in rats. Indian J Pharmacol 2006; 38: 357-8.